Effectively targeting BRAF in melanoma: a formidable challenge

Pigment Cell Melanoma Res. 2008 Aug;21(4):410-1. doi: 10.1111/j.1755-148X.2008.00485.x.
No abstract available

Publication types

  • News

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Benzenesulfonates / therapeutic use
  • Clinical Trials as Topic
  • Drug Delivery Systems / methods
  • Drug Evaluation, Preclinical
  • Humans
  • Indoles / therapeutic use
  • Melanoma / drug therapy*
  • Melanoma / genetics
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Point Mutation / physiology
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
  • Proto-Oncogene Proteins B-raf / genetics
  • Pyridines / therapeutic use
  • Sorafenib
  • Sulfonamides / therapeutic use
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Benzenesulfonates
  • Indoles
  • PLX 4720
  • Phenylurea Compounds
  • Pyridines
  • Sulfonamides
  • Niacinamide
  • Sorafenib
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf